European Heart Journal Advance Access originally published online on December 15, 2004
European Heart Journal 2005 26(3):210-212; doi:10.1093/eurheartj/ehi077
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
European Heart Journal vol. 26 no. 3 © The European Society of Cardiology 2004; all rights reserved.
Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy
1King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
2AstraZeneca, Mölndal, Sweden
3Karolinska Institute, Department of Medicine, Clinical Epidemiology Unit, Stockholm, Sweden
4CALAB Research, Stockholm, Sweden
* Corresponding author. E-mail address: goran.walldius@astrazeneca.com
This editorial refers to ‘Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study’
by C. Meisinger et al., on page 271
| The first 150 words of the full text of this article appear below. |
Introduction
Although low density lipoprotein (LDL) is recognized as the primary lipid-related risk factor, and therefore the primary target for lipid-lowering therapy,1–4 there are in fact several limitations of only using LDL cholesterol (LDL-C) as the primary risk variable.5,6 New data are accumulating which speak in favour of apolipoproteins (apo) as more informative risk indicators/factors. ApoB, which indicates the number of potentially atherogenic lipoprotein particles, and apoA-I, which reflects anti-atherogenic high density lipoprotein (HDL) particles, may be additional lipid-related variables that more accurately indicate cardiovascular (CV) risk than LDL-C. Thus, several studies have shown that apoB and apoA-I are strong predictors of myocardial infarction (MI).7–9 The two largest of these studies are the AMORIS7 and the INTERHEART9 studies which both show a very strong direct relation between a high apoB/apoA-I ratio and an increased risk of fatal MI7 and acute MI (AMI).9 Meisinger et al.10 add another piece of important information along
Physiological and pathophysiological aspects of apoB and apoA-I metabolism
Epidemiological results—prospective studies
ApoB, apoA-I, and prediction of MI in the MONICA/KORA Augsburg study
ApoB and apoA-I—methodological advantages and experience from lipid-lowering trials
A new approach to predict lipid-related CV risk – the apoB/apoA-I ratio paradigm
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
- Christa Meisinger, Hannelore Loewel, Wilfried Mraz, and Wolfgang Koenig
EHJ 2005 26: 271-278.[Abstract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  E. A. Pipe, C. P. Gobert, S. E. Capes, G. A. Darlington, J. W. Lampe, and A. M. Duncan Soy Protein Reduces Serum LDL Cholesterol and the LDL Cholesterol:HDL Cholesterol and Apolipoprotein B:Apolipoprotein A-I Ratios in Adults with Type 2 Diabetes J. Nutr., September 1, 2009; 139(9): 1700 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sierra-Johnson, R. M. Fisher, A. Romero-Corral, V. K. Somers, F. Lopez-Jimenez, J. Ohrvik, G. Walldius, M.-L. Hellenius, and A. Hamsten Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population Eur. Heart J., March 2, 2009; 30(6): 710 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G M Perkins, A Owen, E M Kearney, and I L Swaine Biomarkers of cardiovascular disease risk in 40-65-year-old men performing recommended levels of physical activity, compared with sedentary men Br. J. Sports Med., February 1, 2009; 43(2): 136 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Fernandez and D. Webb The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk J. Am. Coll. Nutr., February 1, 2008; 27(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sierra-Johnson, A. Romero-Corral, V. K. Somers, F. Lopez-Jimenez, G. Walldius, A. Hamsten, M.-L. Hellenius, and R. M. Fisher ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects Eur. Heart J., November 1, 2007; 28(21): 2637 - 2643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Goke, I. Gause-Nilsson, and A. Persson The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes Diabetes and Vascular Disease Research, September 1, 2007; 4(3): 204 - 213. [Abstract] [PDF]
|
|
|
|
 |
|
 C. B. Ingul, E. Rozis, S. A. Slordahl, and T. H. Marwick Incremental Value of Strain Rate Imaging to Wall Motion Analysis for Prediction of Outcome in Patients Undergoing Dobutamine Stress Echocardiography Circulation, March 13, 2007; 115(10): 1252 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lanas, A. Avezum, L. E. Bautista, R. Diaz, M. Luna, S. Islam, S. Yusuf, and for the INTERHEART Investigators in Latin America Risk Factors for Acute Myocardial Infarction in Latin America: The INTERHEART Latin American Study Circulation, March 6, 2007; 115(9): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Florvall, S. Basu, and A. Larsson Apolipoprotein A1 Is a Stronger Prognostic Marker Than Are HDL and LDL Cholesterol for Cardiovascular Disease and Mortality in Elderly Men J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2006; 61(12): 1262 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M Nielsen, O Faergeman, M L Larsen, and A Foldspang Danish singles have a twofold risk of acute coronary syndrome: data from a cohort of 138 290 persons. J Epidemiol Community Health, August 1, 2006; 60(8): 721 - 728. [Abstract] [Full Text] [PDF]
|
|